CT Mason acquired a new position in Gilead Sciences (NASDAQ:GILD) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 53,163 shares of the biopharmaceutical company’s stock, valued at approximately $3,809,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Macquarie Group Ltd. raised its stake in Gilead Sciences by 26.6% during the 3rd quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock valued at $38,836,000 after purchasing an additional 100,741 shares during the period. Toronto Dominion Bank raised its stake in Gilead Sciences by 19.0% during the 2nd quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock valued at $33,445,000 after purchasing an additional 75,364 shares during the period. Maverick Capital Ltd. raised its stake in Gilead Sciences by 161.7% during the 2nd quarter. Maverick Capital Ltd. now owns 24,760 shares of the biopharmaceutical company’s stock valued at $1,753,000 after purchasing an additional 15,300 shares during the period. Oakbrook Investments LLC raised its stake in Gilead Sciences by 1.0% during the 3rd quarter. Oakbrook Investments LLC now owns 384,094 shares of the biopharmaceutical company’s stock valued at $31,119,000 after purchasing an additional 3,621 shares during the period. Finally, Vicus Capital raised its stake in Gilead Sciences by 31.5% during the 3rd quarter. Vicus Capital now owns 11,496 shares of the biopharmaceutical company’s stock valued at $931,000 after purchasing an additional 2,751 shares during the period. 77.91% of the stock is currently owned by hedge funds and other institutional investors.
In other news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $73.14, for a total value of $3,657,000.00. Following the completion of the transaction, the director now owns 3,067,762 shares in the company, valued at approximately $224,376,112.68. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director John Francis Cogan sold 5,833 shares of Gilead Sciences stock in a transaction that occurred on Friday, March 23rd. The stock was sold at an average price of $75.02, for a total value of $437,591.66. Following the completion of the transaction, the director now owns 58,452 shares of the company’s stock, valued at approximately $4,385,069.04. The disclosure for this sale can be found here. In the last quarter, insiders sold 426,934 shares of company stock valued at $33,847,101. Company insiders own 1.30% of the company’s stock.
Shares of Gilead Sciences stock opened at $73.41 on Friday. The company has a market capitalization of $98,310.29, a PE ratio of 8.58, a P/E/G ratio of -1.73 and a beta of 1.19. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67. Gilead Sciences has a one year low of $63.76 and a one year high of $89.54.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company’s quarterly revenue was down 18.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.70 EPS. research analysts forecast that Gilead Sciences will post 6.21 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, March 29th. Stockholders of record on Friday, March 16th were issued a $0.57 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date was Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.11%. Gilead Sciences’s payout ratio is 26.64%.
Several brokerages recently issued reports on GILD. ValuEngine raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Credit Suisse Group set a $80.00 price target on Gilead Sciences and gave the company a “hold” rating in a report on Wednesday, January 3rd. Leerink Swann cut their price target on Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating for the company in a report on Wednesday, February 7th. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price target for the company in a report on Monday, February 19th. Finally, Barclays restated an “overweight” rating and set a $95.00 price target (up previously from $90.00) on shares of Gilead Sciences in a report on Tuesday, March 6th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $88.61.
TRADEMARK VIOLATION WARNING: “CT Mason Acquires New Position in Gilead Sciences (GILD)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/ct-mason-acquires-new-position-in-gilead-sciences-gild.html.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.